Study OEV-121 – Phase I, Safety and immunogenicity of vaccine
Enterotoxin (dmLT) to the vaccine was investigated in a placebo-controlled study. All primary endpoints were met and exceeded, yielding excellent safety and impressive frequency of responders. Both the vaccine formulation with and without the adjuvant were proven safe and well tolerated.
Studies
- All studies
-
Study OEV-128 – Phase IIB Study in children 6-18 months in The Gambia
-
Study OEV-124 – Phase I, Age-descending study in Zambia
-
Study OEV-123 – Phase IIb Safety, diagnostic methodology evaluation and estimated vaccine efficacy in travellers to Benin
-
Study OEV-122 – Phase I/II, Age descending safety and immunogenicity trial in Bangladesh (age ≥6 mo)
-
Study OEV-121A – Phase I, Booster dose memory study
-
Study OEV-121 – Phase I, Safety and immunogenicity of vaccine
-
Study OEV-120 – Phase I, Safety and immunogenicity of a prototype vaccine
-
Study DMID 09-066 – Phase I, dmLT adjuvant safety and immunogenicity
-
